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Abstract
Studies in the past have illuminated the potential benefit of resveratrol as an anticancer (pro-apoptosis) and life-extending
(pro-survival) compound. However, these two different effects were observed at different concentration ranges. Studies of
resveratrol in a wide range of concentrations on the same cell type are lacking, which is necessary to comprehend its diverse
and sometimes contradictory cellular effects. In this study, we examined the effects of resveratrol on cell self-renewal and
differentiation of human mesenchymal stem cells (hMSCs), a type of adult stem cells that reside in a number of tissues, at
concentrations ranging from 0.1 to 10 mM after both short- and long-term exposure. Our results reveal that at 0.1 mM,
resveratrol promotes cell self-renewal by inhibiting cellular senescence, whereas at 5 mM or above, resveratrol inhibits cell
self-renewal by increasing senescence rate, cell doubling time and S-phase cell cycle arrest. At 1 mM, its effect on cell self-
renewal is minimal but after long-term exposure it exerts an inhibitory effect, accompanied with increased senescence rate.
At all concentrations, resveratrol promotes osteogenic differentiation in a dosage dependent manner, which is offset by its
inhibitory effect on cell self-renewal at high concentrations. On the contrary, resveratrol suppresses adipogenic
differentiation during short-term exposure but promotes this process after long-term exposure. Our study implicates that
resveratrol is the most beneficial to stem cell development at 0.1 mM and caution should be taken in applying resveratrol as
an anticancer therapeutic agent or nutraceutical supplement due to its dosage dependent effect on hMSCs.
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Introduction
Resveratrol (3,5,49 – hydroxystilbene) is a naturally occurring
product found in a number of plants, including grapevine, peanut,
blueberry, cranberry, eucalyptus, spruce and the Itadori plant
(Polygonum cuspidatum) [1,2,3,4]. Numerous in vitro and animal
studies have shown that resveratrol possesses a wide range of
biological effects that could benefit human health, including
anticancer chemopreventive and chemotherapeutic activity
[5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23], antioxida-
tion [24,25,26], prolonged lifespan from the yeast to short-lived
vertebrates [27,28,29,30,31], protection from neurotoxicity, ische-
mia and neuron degeneration [32,33,34,35,36,37,38,39], protec-
tion from cardiovascular diseases or injury [40,41,42,43,44],
offsetting the effects of high-calorie diet [45], promoting osteo-
genesis [10,11,46,47,48,49] and inhibiting adipogensis
[48,50,51,52]. The in vitro and ex-vivo anticancer activity of
resveratrol on various human cancer cell types was achieved by
inhibiting free radical formation [24], inducing cell cycle arrest
and apoptosis [6,7,15,16,17,18,19,53,54,55,56], or suppressing the
STAT3 signaling pathway [13]. More recently resveratrol was also
shown to inhibit self-renewal and induce apoptosis in human
cancer stem cells [12,57,58]. On the other hand, the in vivo effect of
resveratrol in prolonging lifespan was largely attributed to the
stimulation of Sirtuins, which deacetylate and destabilize the
activity of p53, resulting in delayed apoptosis and prolonged cell
survival [27,59,60].
Interestingly, there appears to be a dichotomy between the
anticancer (pro-death) and pro-survival effect presented by
resveratrol that has yet to be fully explained. Such functional
discrepancies appear to have resulted from different concentra-
tions of resveratrol exposed to different cells in different
experimental settings. For example, the majority of the in vitro
and ex vivo studies used resveratrol at 10 mM or higher
concentrations, at which it demonstrated anti-proliferation and
pro-apoptotic activity [6,7,8,9,10,12,13,15,16,17,18,24,55,56,57].
However, except for the study with saccharomyces cerevisiae in which
resveratrol was applied at 10 mM in culture medium and found to
increase life span by 70% [27], other studies eliciting the lifespan-
extending effect of resveratrol were all carried out in vivo using
animal models. The animals were given resveratrol orally in
various regimens without being assessed of the bioavailability of
resveratrol and/or its metabolites [28,29,30]. While absorption of
resveratrol through oral ingestion is high, its bioavailability has
been demonstrated to be low in humans. An oral dose of 25 mg
resulted in a peak plasma level of 2 mM and a half-life of around
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with plasma concentration of resveratrol detected at 1.3 mMi n
mice fed with an oral dose of 100 mg/kg/day [17]. Such low in
vivo bioavailability suggests that its observed lifespan-extending
effect was derived at a much lower concentration range as
compared to that of its anti-proliferation and pro-apoptotic effect.
Indeed, differential effects of resveratrol at low vs. high dose/
concentrations have been observed in a number of studies
[14,19,21,54,62,63,64,65,66,67,68], though in many cases, low
concentration effects were not addressed and focus was placed on
the anti-proliferation and pro-apoptosis effect observed at high
concentrations instead [14,19,21,62,63,64]. In general, resveratrol
promotes cell proliferation and inhibits apoptosis at concentrations
below 10 mM in tumor cells lines [14,19,21,62,63,65,66,67], while
in normal cell lines such as endothelial cells, growth stimuli were
observed at 1 mM or below [54,64,68]. Indeed, in one in vivo study
it was shown that, in contrary to its widely demonstrated
anticancer activity in vitro, oral uptake of resveratrol at 16.5 mg/
kg three times a week by mice xenografted with human breast
cancer cells stimulated tumor growth compared to vehicle-treated
animals [69], presumably due to low bioavailability in vivo.
Despite the lack of full understanding of resveratrol’s dynamic
actions, studies of this compound have inspired its clinical trials
and commercialization as a nutraceutical [70,71]. One potential
cell target for resveratrol through oral or intravenous injection is
the adult stem cells residing in different tissues and organs.
However, limited studies have examined the effect of resveratrol
on stem cell development [10,11,46,47,72,73]. Moreover, only
one study used normal primary human stem cells, which briefly
described the enhancing effect of resveratrol in a dosage
dependent manner (0.01 mMt o1 0mM) on the proliferation rate
and osteogenic differentiation of hMSCs after short-term exposure
[11]. HMSCs reside in a number of tissues or organs, including
bone marrow, adipose tissue, umbilical cord blood and fetal liver,
and are one of the most abundant adult stem cell types in the
body. They are capable of self-renewal and upon receiving
appropriate external stimuli, could differentiate into multiple
mature cell types, such as osteocytes, adipocytes and chondrocytes.
As with other adult stem cell types, they are thought to serve as the
reservoir for maintaining tissue homeostasis and tissue repair in
vivo.
To gain better understanding of the effect of resveratrol on
hMSCs development (adipose tissue derived), we examined how
short-term (#2 weeks) vs. long-term (4–10 weeks) exposure to
resveratrol at various concentrations (0.1, 1, 5 & 10 mM) could
alter these cells’ capacity to self-renewal and differentiate. Our
results demonstrated a dosage dependent effect of resveratrol on
hMSCs self-renewal as a result of its combinatorial effect on cell
senescence rate, cell doubling time and cell proliferation rate, as
well as a dosage- and, in the case with adipogenic differentiation,
time-dependent effect on hMSCs differentiation.
Results
Resveratrol exerts dosage dependent enhancing vs.
inhibitory effect on the self-renewal rate of hMSCs
During short-term culture of hMSCs, it was visually noted that
cells treated with 5 or 10 mM resveratrol expand slower than cells
treated with a-MEM basal media (BM) solvent or lower
concentration resveratrol. To confirm this observation, cells at
passage 4 (P4) were plated at equal density and cultured with
resveratrol or BM (controlled for the same amount of BM in
10 mM resveratrol) for 30 days. Every 6 days cells were manually
counted and split identically among all treatment groups.
Figure 1.A. shows that while 0.1 mM resveratrol seemed to
provide slight growth advantage over BM treated cells, higher
concentrations showed a dosage dependent inhibitory effect. To
further confirm and examine whether the observed enhancing/
inhibitory effect occurred only during early treatment or
throughout the duration, cells pretreated for 0 (0D-PT), 9 (9D-
PT), 12 (12D-PT) or 30 (30D-PT) days of resveratrol or BM were
plated at equal low density and treatment was continued until cells
of one treatment group reached 100% confluency (regardless of
the confluency of the other groups), when resazurin assay was
carried out to assess the relative number of live cells in each
treatment condition. The OD reading of resazurin solution is
inversely correlated to the numbers of live cells [74]. At all 4
different pretreatment time points, 0.1 mM resveratrol treatment
resulted in the lowest OD reading and therefore the highest cell
numbers, whereas higher concentrations of resveratrol resulted in
a dosage dependent increase in OD readings (Figure 1.B.),
demonstrating a similar trend observed by manual cell counting.
The results indicated that resveratrol enhanced cell self-renewal
rate at 0.1 mM, had no significant effect at 1 mM, and inhibited
cell self-renewal at 5 and 10 mM.
Cell self-renewal rate could be affected by cytotoxicity, cell
senescence rate, cell apoptosis rate, cell cycle progression rate (cell
doubling time) and cell proliferation rate (percentage of cells
entering cell cycle). To examine which are the contributing factors
to the altered cell self-renewal rates in response to resveratrol
treatments, the following assays were carried out.
Resveratrol treatment does not cause acute cytotoxicity
in hMSCs
To examine whether resveratrol at high concentrations could be
toxic to the cells, a lactate dehydrogenase (LDH)-based cytotox-
icity assay was carried out, which measures LDH activity released
from the cytosol of damaged cells into the supernatant. Untreated
P4 cells (0D-PT) were plated at equal density across all wells on 96-
well plates and then subjected to BM or resveratrol treatment, with
12 wells per condition. After 24 hours, LDH activity was
measured and no significant difference was observed among BM
and resveratrol treatment groups (Figure 2). Similar results were
obtained when LDH activity was subsequently measured in
combined supernatant from 5 days of daily collection for each
treatment group with fresh media change after each collection
(data not shown). This indicates that resveratrol does not cause
acute cytotoxicity at concentrations tested. In addition, LDH
activity was examined in cells pretreated for 6 (6D-PT), 25 (25D-
PT), 35 (35D-PT) or 41 days (41D-PT) of BM or resveratrol and
plated at equal density across different treatment groups (Figure 2).
In 6D-PT cells, resveratrol treatment at 5 mM or below had
reduced LDH activity as compared to BM, whereas at 10 mMi ti s
not significantly different from BM or the other resveratrol
treatment groups. In the other pretreatment groups, all resveratrol
treatments slightly but significantly increased LDH activity
compared to the BM group (except for 1 mM at 41D-PT), but
significant differences between low (0.1 and 1 mM) vs. high (5 or
10 mM) resveratrol treatment only appeared in 41D-PT cells
(P,0.01). This indicated that any potential acute cytotoxicity by
resveratrol was unlikely a pivotal factor in conferring its differential
effect on cell self-renewal rate at different concentrations, as it
consistently promoted cell self-renewal at 0.1 mM and exerted
opposite effect at 5 and 10 mM throughout both short- and long-
term treatments as shown above.
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apoptotic effect in hMSCs
To examine its potential effect on cell apoptosis rate, untreated
cells (0D-PT) or cells pretreated with BM or resveratrol for 30 days
(30D-PT), were subjected to 6 or 5 days of treatment respectively
after equal density plating, followed by co-staining with Annexin-
V-Fluorescein and Propidium iodide (PI) solution. Annexin-V
(green) labels both apoptotic and necrotic cells whereas PI (red)
labels only necrotic cells (Figure 3). In 0D-PT-6D-RSV cells, no
clear trend could be identified among all treatment groups in
either the percentages of apoptotic (G) or necrotic (G+R) cells
(Table 1). In 30D-PT-5D-RSV cells, all resveratrol treatments
(except for 1 mM) resulted in higher percentages of necrotic (G+R)
cells than the BM group (Table 1). In addition, there appeared to
be a very subtle dosage dependent upward trend in the
percentages of apoptotic (G) cells among the resveratrol treatment
groups (Table 1).
In the acute cytotoxicity assay described earlier, LDH activity
was measured on cells treated with BM or resveratrol in AM
media for 24 hrs after equal density plating. Such time restriction
is necessary in order to minimize the effect of cell density change
on the LDH readout after prolonged cell culture. To examine
whether apoptotic rate is affected by resveratrol treatment under
similar conditions, cells pretreated with BM or resveratrol for 25
days were plated at equal density and subjected to only 24 hours of
culture in corresponding regular CM-based treatment media
(25D-PT-1D-RSV) before co-staining with Annexin-V/PI solu-
tion. The percentages of necrotic (G+R) cells, but not apoptotic
(G) cells, trended higher in all resveratrol treatment groups than
the BM group. In addition, no trend was observed across
resveratrol treatments (Table 1). Since the LDH assay required
using an assay media (AM) with low fetal bovine serum (1%),
instead of the regular CM media, for reconstituting BM or
resveratrol treatment solution, we also carried out Annexin V/PI
staining on 35D-PT cells plated at equal density followed by
24 hours of BM or resveratrol treatment in AM media as in the
LDH assay (35D-PT-1D-RSV). Similar to the 25D-PT-1D-RSV
cells, all resveratrol treatments (except for 1 mM) resulted in higher
percentages of necrotic (G+R), but not apoptotic (G) cells than the
BM group, and no trend could be identified among the resveratrol
treatment groups in either category (Table 1). In contrary to in
regular CM media, it was noted that in AM media, majority of
green cells were also stained red. The increased percentages of
necrotic cells, but not apoptotic cells, could have contributed to the
observed slight increase of LDH activities by resveratrol-treated vs.
BM-treated groups in the LDH assays carried out on the 25D-PT
and 35D-PT cells.
Overall, the above results indicated that resveratrol had no
significant effect on cell apoptosis rate at concentrations tested
during short-term treatment and therefore would not have likely
contributed to its dosage-dependent effect on cell self-renewal rate,
but cells subjected to prolonged resveratrol exposure may
demonstrate a subtle dosage dependent increase in apoptotic rate,
which could contribute to the long-term effect of resveratrol on cell
self-renewal.
Figure 1. Resveratrol exerts dosage dependent enhancing vs. inhibitory effect on the self-renewal rate of hMSCs. A). Cells were plated
at equal density and cultured in different concentrations of resveratrol continuously for 36 days during which cells were counted and split at equal
ratio every 6 days. *: p,0.01. B). Cells pretreated with resveratrol or BM for 0 (0D-PT), 9 (9D-PT), 12 (12D-PT) or 30 (30D-PT) days were seeded at 8000
cells/well and continued to culture in corresponding media until resazurin assay. Error bars represent standard deviation (triplicates in each treatment
condition). *: p,0.05 vs. BM.
doi:10.1371/journal.pone.0037162.g001
Figure 2. Resveratrol does not cause acute cytotoxicity in hMSCs at concentrations tested. Untreated P4 cells (0D-PT) or cells pretreated
for 6 (6D-PT), 25 (25D-PT), 35 (35D-PT) or 41 days (41D-PT) were plated at equal density and then subjected to 24 hours of treatment in
corresponding BM or resveratrol media before LDH assay. AM: assay media; AM alone: no cells; AM alone w/RSV: no cells and the highest
concentration of RSV in the group was used; 1% triton X-100 in AM: positive control (all values .2.5). Data presented were the mean values of each
treatment type. Error bars represent standard deviation. *: p,0.05 vs. BM.
doi:10.1371/journal.pone.0037162.g002
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To examine cell senescence rate, beta-galactosidase activity was
measured as an indicator of cellular senescence [75]. Early passage
cells (P4 & P5, corresponding to 0D-PT and 6D-PT cells
respectively) were plated at similar density before being subjected
to resveratrol or BM treatment until they reach about 90% or less
confluency. Cells were then fixed and stained in X-gal solution and
counterstained in neutral red solution (Figure 4.A). Compared to
BM treated cells, cells treated with 0.1 or 1 mM resveratrol had
significantly less cells stained positive for beta-galactosidase activity
compared to those treated with 5 or 10 mM resveratrol
(Figure 4.B.), indicating that at 0.1 or 1 mM, resveratrol inhibits
senescence, but at 5 and 10 mM, it promotes senescence. To
examine whether cells pretreated with resveratrol or BM for
extensive period of time respond similarly, cells pretreated with
resveratrol or BM for 30 days (30D-PT) were plated at similar
density and continued in their corresponding media until
senescence assay. At 0.1 mM, resveartrol remained slightly
inhibitory to senescence compared to BM, while at 1 mMo r
higher, it drastically increased the senescence rate at 3–9 times
higher than BM in a dosage dependent manner (Figure S1). The
results indicated that resveratrol consistently inhibited senescence
at 0.1 mM and promoted senescence at 5 or 10 mM, while at
1 mM, it inhibited senescence during short-term pretreatment but
significantly enhanced senescence after long-term exposure.
Long-term resveratrol pretreatment prolongs cell-
doubling time in hMSCs in a dosage dependent manner
To examine cell-doubling time, both untreated early passage
cells (0D-PT) and cells pretreated for 30D with BM or RSV (30D-
PT) were plated at 1–2 cells/well density in CM in 96-well plates
and changed to BM or RSV the next day (0 hr time point). Total
of 10 wells were selected for each treatment group and cells in
each well were recorded at 0 hr and every 12-hr intervals until
72 hrs or longer. To minimize error, cell doubling time at each
time point beyond 0 hr was calculated based on the average cell
counts from all 10 wells for each treatment group and the average
doubling time was then calculated from all time points. Media was
changed every 48 hrs. For 0D-PT cells, the cell-doubling time
appeared to be steadily reduced by 0.1 mM resveratrol and
increased by 5 or 10 mM resveratrol as compared to BM, though
none of the differences was considered as statistically significant
(P.0.05) (Figure 5). On the other hand, for 30D-PT cells, cell-
doubling time was clearly significantly increased in 5 mMo r
10 mM treated cells compared to BM treated cells. To verify
whether this increase in cell-doubling time was a result of
accumulating effect of resveratrol treatment over time or a result
of increased sensitivity of response to resveratrol in aging cells, age-
matched cells that have been cultured in CM (30D-CM) were
subjected to identical assay. Similar to the 0D-PT cells, no
statistically significant differences were observed between resver-
atrol vs. BM treated groups, though the overall cell-doubling time
of the 30D-CM group was increased as compared to that of the
0D-PT group (P,0.01) (Figure 5), which is consistent with visual
observations that late passage cells take longer to reach 100%
confluency than earlier ones when plated at the same density (data
not shown). The above results indicated that long-term resveratrol
exposure at 5 or 10 mM significantly prolonged cell-doubling time.
Resveratrol increased cell proliferation rate in a time and
dosage dependent manner
To examine cell proliferation rate, cells pretreated in resveratrol
or BM for 0 (0D-PT), 12 (12D-PT) or 30 (30D-PT) days were
subjected to Click-iT EdU (5-ethynyl-29-deoxyuridine) assay. Cells
were plated in similar density in their perspective media and
cultured for 6 (0D-PT) or 5 (12D-PT & 30D-PT) more days
respectively until reaching around 50–70% confluency when EdU,
a nucleoside analog of thymidine, was added. Duplicate cells were
fixed 6 hours or 12 hours later for detection of incorporated EdU.
The labeling duration was determined based on the average cell-
doubling time for hMSCs and two different time points were
chosen for parallel confirmation. The percentage of green (EdU-
labeled proliferating cells) vs. grey (Hoechst-labeled total cells) cells
was determined by counting cells across each well of 24-well plates
(in between 800 to 2100 cells/well, depending on treatment
Figure 3. Apoptosis assay of hMSCs. Representative images of cells
stained positive for annexin-V-fluorescein (green) alone or positive for
both annexin-V-fluorescein and propidium iodide (PI, red) are
presented. Scale: 50 mm.
doi:10.1371/journal.pone.0037162.g003
Table 1. Resveratrol does not affect cell apoptosis rate in
hMSCs.
0D-PT-6D-RSV 30D-PT-5D-RSV
AVG (G+R) AVG(G) AVG (G+R) AVG(G)
BM 0.49% 2.46% 1.05% 6.29%
0.1 mM 0.44% 3.43% 1.32% 5.87%
1 mM 0.27% 2.04% 1.06% 6.80%
5 mM 0.51% 2.81% 1.54% 7.07%
10 mM 0.17% 1.69% n/a n/a
25D-PT-1D-RSV 35D-PT-1D-RSV
AVG (G+R) AVG(G) AVG (G+R) AVG(G)
BM 0.31% 7.58% 3.64% 1.04%
0.1 mM 0.62% 4.75% 5.04% 1.11%
1 mM 0.48% 4.34% 3.61% 0.88%
5 mM 0.67% 3.92% 5.55% 0.89%
Annexin-V-FLUO staining was carried in cells pretreated with BM or resveratrol
for 0 or 30 days, followed by 6 (0D-PT-6D-RSV) or 5 (30D-PT-5D-RSV) more days
of treatment respectively after equal density plating, and cells pretreated with
BM or resveratrol for 25 or 35 days, followed by 1 day of additional treatment
after equal density plating (25D-PT-1D-RSV or 35D-PT-1D-RSV). The percentage
of apoptotic cells stained green (G) alone or necrotic cells stained both green
and red (G+R) were counted from two wells of each treatment group. The total
cells counted from 2 wells of each treatment group exceeded 4000 cells.
doi:10.1371/journal.pone.0037162.t001
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short period of resveratrol treatment (6–17 days), there was a
dosage dependent enhancing effect on the proliferation rate of
hMSCs, culminating at 10 mM. However, after prolonged
treatment (35 days), proliferation rate dropped significantly in
response to 1 mM resveratrol, but remained up regulated by
10 mM.
Resveratrol increased the percentage of S-phase cells in a
dosage dependent manner
Increased cell-doubling time and cell proliferation rate would
suggest increased representation of S and/or G2/M phase cells in
high concentration resveratrol treated cells. To verify this, we
performed flow cytometry based cell cycle analysis on cells
pretreated with resveratrol or BM for 0 (0D-PT) or 30 (30D-PT)
days, followed by 6 (0D-PT) or 4 (30D-PT) more days of treatment
respectively after equal density plating. As shown in table S1 and
figure 7, in both cases, resveratrol caused a dosage dependent
increase in the representation of S phase cells. In 0D-PT cells, only
10 mM resveratrol resulted in increased representation of G2/M
phase cells, whereas in 30D-PT cells, both 5 and 10 mM did. The
discrepancy observed between short- and long- term resveratrol
treatment could have been due to changes in cellular response as a
result of long-term resveratrol treatment or as a result of cellular
aging in vitro for the long-term treated cells. To distinguish these
two scenarios, cells were cultured in regular CM for hMSCs in
parallel to cells cultured in resveratrol or BM for 30 days, followed
by 4 days of resveratrol or BM exposure before cell cycle analysis
(30D-CM). The distribution of G2 phase cells were increased by
both 5 and 10 mM resveratrol treatment, suggesting that it was in
vitro cellular aging that had caused the discrepancy observed
between short- vs. long- term exposure. Additional repeat with
cells pretreated with BM or resveratrol for 42 days (42D-PT)
followed by 4 additional days of culture after equal density plating
demonstrated similar results as those of 34D-RSV (Table S1). The
above results indicate that regardless of age or duration of pre-
exposure to resveratrol, the percentage of hMSCs residing in both
S and G2/M phases (S+G2/M) is significantly increased by
resveratrol in a dosage dependent manner, consistent with its effect
in cell doubling time and cell proliferation rate.
In summary of the above results, at low concentration (0.1 mM),
resveratrol promotes cell self-renewal of hMSCs by reducing cell
senescence rate and perhaps by increasing cell proliferation rate
and reducing cell-doubling time as well, whereas at high
concentrations (5 or 10 mM), resveratrol inhibits cell self-renewal
of hMSCs by significantly increasing cell senescence rate and cell-
doubling time, which might be partly offset by increased cell
proliferation rate. Such inhibitory effect may also be exacerbated
by enhanced apoptotic rate after long-term exposure.
Resveratrol regulates the expression of genes implicated
in cell cycle regulation, cell senescence and longevity
In light of the observed effect of resveratrol on cell cycle,
senescence and proliferation, we examined the expression of a
number of genes implicated in those biological processes, including
c-Myc, Cdk2, p16, p21, p53, Cyclin D1, Birc4, Birc5, Sirtuin1 and
Sirtuin2, in cells pretreated with resveratrol for 3 days (3D) or 5
days (5D). Sirtuin1 and Sirtuin2 are thought to be critical players
in prolonging life span [27,59,60]. Birc4/XIAP and Birc5/
Survivin are members of the Inhibitors of Apoptosis (IAPs) family
that suppress caspase activities [76]. Cdk2 promotes cells entering
cell cycle whereas p21 is a cell cycle inhibitor. Among those genes,
Sirtuin1, Sirtuin2, Birc4, Birc5 and Cdk2 consistently demonstrated
altered expression in response to resveratrol. Sirtuin1, Sirtuin2, Birc4
and Birc5 were weakened in 5 or 10 mM resveratrol pretreated
cells as compared to BM treated cells, whereas Cdk2 demonstrated
enhanced expression (Figure 8). The relative changes observed in
all genes appeared subtle but statistically significant, and correlate
to increased senescence rate and higher percentage of S phase cells
in response to high concentration resveratrol exposure.
Resveratrol promotes osteogenic differentiation of
hMSCs in a dosage dependent manner
HMSCs can be induced to undergo osteogenic or adipogenic
differentiation in vitro when exposed to appropriate stimuli. We
therefore assessed how different concentrations of resvertrol could
affect both processes after short- or long-term exposure. When
exposed to osteogenic inducing media (OIM), hMSCs differentiate
into mature bone cells characterized by extracellular matrix
Figure 4. Resveratrol exerts dosage dependent anti- vs. pro-
senescence effect on hMSCs. A). Cells were stained in X-gal (blue
color) and neutral red solution (red color). Images were taken at 2006
magnification. B). Percentages of senescent cells vs. total cells were
determined based on images taken. At least 184 total cells from each
treatment condition were counted. Column represents the relative fold
changes of percentage of cells undergoing senescence in each
treatment group normalized to the value obtained in the BM treated
cells. Data was obtained from three independent experiments. Error
bars represent standard deviation. *: p#0.01 vs. BM.
doi:10.1371/journal.pone.0037162.g004
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treatment of resveratrol with OIM could affect the outcome. Early
passage cells (P4) at 100% confluency were exposed to OIM and
resveratrol at different concentrations for 14 to 21 days before
alizarin red staining, which detects calcium phosphate deposit, a
major component of mineralized extracellular matrix. Consistent-
ly, resveratrol enhanced osteogenic differentiation at 0.1 or 1 mM
as indicated by increased calcium phosphate deposit, but exerted
opposite effect at 5 or 10 mM (Figure 9A & B). This is also
confirmed by examining the activity of Alkaline Phosphatase
(ALP), an early marker of osteogenic differentiation [78,79]. ALP
staining was clearly enhanced by both 0.1 and 1 mM resveratrol,
with increased intensity in individual cells and increased cell
density (Figure 9B). In the presence of 5 mM resveratrol however,
ALP staining intensity is enhanced in some individual cells as well,
but the overall intensity is reduced due to reduced cell density
(Figure 9B).
To further gauge the thresholds at which resveratrol exerts
enhancing or inhibitory effect under such condition, cells were
treated with OIM and resveratrol in a broader concentration
range including 0.01, 0.1, 1, 2, 3 and 5 mM. At 0.01 mM,
resveratrol had minimum effect on OIM activity. At 0.1 mMi t
reached maximum enhancing effect, which gradually decreased as
concentration increased (Figure S2). In addition, we examined the
effect of resveratrol on hMSCs derived from bone marrow
(hMSCs-Bm), which are characteristically identical to hMSCs
derived from adipose tissue (hMSCs-Ad), the cell type chosen in
this study. Not surprisingly, these cells responded to resveratrol
similarly as hMSCs-Ad (Figure S2).
To examine how resveratrol treatment alone could change the
cells’ capacity to undergo osteogenesis, cells were pretreated with
BM or resveratrol for 4, 9, 26, 37 and 67 days (4D, 9D, 26D, 37D
or 67D respectively), with identical passaging among all treatment
groups throughout the culture, followed by OIM induction.
Similar to concurrent treatment, resveratrol promoted osteogen-
esis at 0.1 or 1 mM, but inhibited this process at 5 or 10 mM
(Figure 9A & B).
However, since resveratrol enhanced cell self-renewal rate at
0.1 mM and inhibited cell self-renewal at 5 and 10 mM, we
examined whether cell numbers could have played a role in the
above outcome by re-plating resveratrol-pretreated cells at equal
density among all treatment groups before OIM induction in
order to compensate the effect of resveratrol on cell self-renewal.
Interestingly, under such condition, resveratrol clearly exerted a
dosage dependent enhancing effect at all concentrations after long-
term pretreatment (30 or 46 days, Figure 9A & B), suggesting that
resveratrol intrinsically promoted osteogenic differentiation capac-
ity of hMSCs in a dosage dependent manner, though at high
concentrations such effect was offset by its inhibitory effect on cell
self-renewal.
Resveratrol exerts differential effect on adipogenic
differentiation of hMSCs in a time dependent manner
When exposed to adipogenic inducing media (AIM), hMSCs
differentiate into mature fat cells characterized by oil droplets
inside the cells. Similar to our study with osteogenic differentia-
tion, the effect of resveratrol on adipogenic differentiation was
carried out in three different schemes: concurrent treatment,
pretreatment and equal density plating. When cells were exposed
to AIM and resveratrol/BM concurrently for 18 days, there was a
dosage dependent inhibitory effect (Figure 10A), which was also
observed with hMSCs-BM (data not shown). When cells were
pretreated with BM or resveratrol continuously for 12 or 26 days
(12D or 26D respectively), with identical passaging among all
treatment groups throughout the culture, followed by AIM
induction, they exhibited differential outcomes. After 12D
pretreatment, resveratrol inhibited adipogenesis in a dosage
dependent manner similar to concurrent treatment. However,
after 26D pretreatment, resveratrol promoted adipogenesis,
though the effect was diminished at 10 mM, which was likely
Figure 5. Resveratrol pretreatment prolongs cell-doubling time of hMSCs in a dosage dependent manner. Untreated early passage
cells (0D-PT), untreated late passage cells (30D-CM) and cells pretreated with resveratrol or BM for 30 days (30D-PT) were plated at 1–2 cells/well
density and exposed to the same resveratrol or BM treatment for 72 hours or longer for cell-doubling time assay. Data presented are the mean values
of 2 independent experiments for each experimental set. Error bars represent standard deviation. *: p,0.05 vs. BM.
doi:10.1371/journal.pone.0037162.g005
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this concentration (Figure 10A & B). To compensate its effect on
cell self-renewal, cells pretreated with resveratrol or BM for 12, 30
or 46 days (12D, 30D or 46D respectively) were re-plated at equal
density before being subjected to AIM induction. Except for at
0.1 mM, resveratrol inhibited adipogenesis after 12D pretreatment
but promoted it after 30D pretreatment (Figure 10A & B). This
suggests that the enhancing effect of resveratrol at 0.1 mM after
26D-pretreatment without cell density correction was likely due to
enhanced cell self-renewal. Interestingly, after 46D pretreatment,
resveratrol exhibited enhancing effect on adipogensis at all
concentrations after equal density plating (Figure 10A & B). The
above results indicated that resveratrol had an overall inhibitory
effect on adipogensis during short-term treatment, but after long-
term treatment, it reversed to enhance adipogensis.
Resveratrol regulates the expression of genes implicated
in osteogenesis and adipogensis
Osteogenic differentiation is characterized by the expression of
a number of genes including ALPL (liver/bone/kidney specific
isoform of Alkaline Phosphatase), an early marker and Osteocalcin,a
late-stage differentiation marker [79]. On the other hand,
adipogenic differentiation is characterized by the expression of
PPARc2, CEBPa and others [80]. Semi-quantitative RT-PCR was
carried out to examine the expression levels of the above genes on
cells subjected to 3 or 7 days of BM or resveratrol treatment with
OIM (3/7D-CT OIM) or AIM (3/7D-CT AIM) concurrently,
and cells pretreated with BM or resveratrol for 12 days followed by
3 or 7 days of OIM (12D PT-3/7D OIM) or AIM (12D PT–3/7D
AIM). Expression of ALPL was weakly but significantly up
regulated in both 3D-CT OIM and 12D PT-3D OIM resveratrol
samples vs. BM control samples (Figure 11A & B). Expression of
Osteocalcin was also slightly up regulated in 7D-CT OIM
resveratrol samples vs. BM samples. On the other hand,
expression of both PPARc2 & CEBPa was significantly down
regulated in 12D PT-7D AIM resveratrol samples compared to
BM samples (Figure 11A & B), and similar results were observed in
3D-CT AIM samples as well (data not shown). The above results
were consistent with the phenotypic observation of resveratrol in
promoting osteogenesis and inhibiting adipogenesis during short-
term exposure.
In summary, our studies demonstrated: I) hMSCs self-renewal
was slightly enhanced by resveratrol at 0.1 mM, unchanged at
1 mM but significantly inhibited at 5 or 10 mM, regardless of the
pretreatment duration. Such effect was a result of combined
actions on cell senescence, cell cycle progression and cell
proliferation, whereas apoptosis did not likely play a role during
short-term treatment, but may exert a subtle effect after prolonged
exposure to resveratrol. At 0.1 mM, resveratrol inhibited senes-
cence rate, without significantly altering cell doubling time or cell
proliferation, regardless of pretreatment duration. At 1 mM, short-
term resveratrol pretreatment reduced senescence rate, while long-
term treatment resulted in significant increase. Neither short- nor
long-term treatment had significant effect on cell doubling time
but cell proliferation rate was drastically reduced after long-term
treatment. In contrary, at 5 or 10 mM, both short- and long-term
resveratrol pretreatment significantly increased cell doubling time,
cell senescence rate and the percentage of cells in the (S+G2/M)
phase. Interestingly, cell proliferation rate based on EdU assay was
also significantly stimulated by 5 and 10 mM resveratrol. II)
hMSCs were differentially regulated by resveratrol in terms of its
osteogenic and adipogenic differentiation capacity. Regardless of
the pretreatment duration, resveratrol enhanced osteogenic
differentiation capacity of hMSCs in a dosage dependent manner,
with the strongest induction at 10 mM, though this was also offset
by its inhibitory effect on cell self-renewal at high concentrations.
On the other hand, short-term pretreatment inhibited while long-
term pretreatment promoted adipogenic differentiation of these
cells. Finally, molecular studies also showed differential effect of
resveratrol at different concentrations on the expression of a
number of genes involved in cell cycle, cell apoptosis, cell survival,
adipogensis and osteogenesis, providing some molecular basis for
its differential effect on hMSCs self-renewal and differentiation.
Discussion
Our study revealed distinct and much more dynamic actions on
both cell self-renewal and differentiation of hMSCs conferred by
different concentrations of resveratrol, as compared to a previous
study [11]. At 0.1 mM, resveratrol appears to offer the most
Figure 6. Resveratrol pretreatment affects cell proliferation
rate of hMSCs in both time and dosage dependent manner. A).
Duplicate wells of cells pretreated with resveratrol or BM for 0 (0D-PT),
12 (12D-PT) or 30 (30D-PT) days, followed by 6 (0D-PT) or 5 (12D-PT &
30D-PT) more days of treatment respectively after similar density
plating were fixed and stained at 6 or 12 hrs post EdU addition. Cells
labeled with EdU were green (indicated by arrows) whereas unlabeled
cells appeared grey from Hoescht 33342 staining (image taken using
UV/Blue dual filter at 2006 magnification). B). Percentages of green
cells were normalized to the value in the BM treated cells. Error bars
represent standard deviation. *: p,0.05 vs. BM.
doi:10.1371/journal.pone.0037162.g006
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both short- and long-term exposure, inhibiting adipogenesis over
short-term exposure, but promoting adipogenesis over long-term
exposure. At 5 or 10 mM however, resveratrol inhibits cell self-
renewal, but regulates osteogenesis and adipogenesis similarly as at
0.1 mM. Corresponding to the opposing effect of resveratrol at low
vs. high concentrations on the self-renewal of hMSCs, genes
implicated in cell survival (Sirtuin 1, Sirtuin 2, Birc5 & Birc4) were
up-regulated by lower concentration resveratrol, but inhibited by
higher concentration resveratrol. It is noteworthy that while
hMSCs exposed to high concentration resveratrol exhibited
increased cell senescence rate and cell doubling time, their
proliferation rate was increased too, which corresponded to
enhanced Cdk2 expression. Increase in proliferation rate however
may have limited effect to offset the inhibitory effect on self-
renewal conferred by the increases in senescence and cell doubling
time, as cells entering cell cycle would end up undergoing S-phase
arrest and have prolonged cell-doubling time. The mechanism
underlying the biphasic dose response on gene expression
regulation is unclear and would be of great interest for future
studies. It is important to note that similar type of dose-dependent
effect (termed hormesis) has been observed with numerous other
compounds, and related studies have been collected in a database
[81,82,83].
It is intriguing that resveratrol exerts opposing effect on
adipogenesis during short- vs. long-term treatment, however it is
not clear whether this is due to differential response of young vs.
aging cells, as long-term pretreated cells are also older. Our study
on cell cycle analysis comparing earlier (0D-PT) vs. later passage
cells (30D-CM) demonstrated that there was indeed differential
response to the same concentration resveratrol between these two
populations (Figure 7 and Table S1). Future studies would be
needed to fully elicit potential differential response to resveratrol
by young vs. aging cells derived from young vs. old donors
respectively, as well as those derived from earlier vs. later passage
cells. Along the line, it is important to point out that the effect of
resveratrol on hMSCs in vivo may also be modulated by estrogen
activity present and different individuals (female vs. male; young
vs. old) may have different responding thresholds [14]. It is also
interesting to point out that the effect of resveratrol on self-renewal
has a greater masking effect on the outcome of osteogenic
differentiation as compared to on adipogenic differentiation. For
osteogenic differentiation, long-term continuous pretreatment with
higher concentration resveratrol resulted in significant reduction of
osteogenic activity (Figure 9A & B), which was then reversed when
cell density was compensated. On the contrary, for adipogenic
differentiation, continuous pretreatment with high concentration
(5 mM) resveratrol for 26 days still promoted adipogenesis despite
its inhibitory effect on cell self-renewal at this concentration, and
the enhancing effect was only diminished at 10 mM, which was
reversed when cell density was compensated (Figure 10A & B).
This is likely due to the fact that cells undergo great clonal
expansion during osteogenic differentiation, whereas during
adipogenic differentiation, cells undergo very limited clonal
Figure 7. Resveratrol increased the percentage of S-phase cells in a dosage dependent manner. Flow cytometry was performed to
analyze cell cycle distributions on cells pre-exposed to resveratrol or BM for 0 (0D-PT) or 30 (30D-PT) days, followed by 6 (0D-PT) or 4 (30D-PT) more
days of treatment respectively after equal density plating, and cells cultured in regular hMSCs media (CM) for 30 days prior to 4 days of resveratrol or
BM treatment following equal density plating (30D-CM). Stacked columns represent the relative distribution of cells in S, G2/M or (S+G2/M) phases in
each treatment group normalized to the value in the BM treated cells (see Table S1). Data presented are the mean values of 2 or 3 independent
experiments for each experimental set. All duplicate experiments had similar outcomes.
doi:10.1371/journal.pone.0037162.g007
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inhibitory effect on osteogenic differentiation by high concentra-
tions of resveratrol when density is not compensated.
Our results suggest that to achieve its anticancer effect at 10 mM
or higher concentrations, resveratrol might have adverse effect on
hMSCs development, and potentially other normal cell types in
the body as well. Our results also suggest that people taking
resveratrol supplement should take precaution on the dosage
intake on a daily basis. Commercial resveratrol is available at
between 50 mg and 300 mg per dosage form. A 25-mg oral dose
resulted in peak plamsa levels of resveratrol and metabolites at
about 2 mM and a plasma half-life of 9.260.6 h [61]. While it is
Figure 8. Resveratrol regulates the expression of genes implicated in cell cycle, cell senescence and longevity regulation. A).
Representative gel images of gene expression examined by semi-quantitative RT-PCR on cells pretreated with BM or resveratrol for 3 or 5 days.
Expression of internal control gene Hsp90 from the same batch of cDNA for each gene is shown in the bottom row. B). Expression of each gene in
resveratrol treated cells was quantified relative to that in BM treated cells and normalized by the expression level of housekeeping gene Hsp90. Data
shown are the mean values of three repeats. Error bars represent standard deviation. *: p,0.05 vs. BM.
doi:10.1371/journal.pone.0037162.g008
Figure 9. Resveratrol modulates osteogenic differentiation of hMSCs in a dosage dependent manner. A). Calcium phosphate deposit
was stained by alizarin red solution and subsequently quantified under three different treatment schemes: concurrent treatment, pretreatment and
equal density. Missing columns are a result of detached cells. B). Images of alizarin red stained cells under different treatment conditions. 7D-
Concurrent treatment cells were stained for alkaline phosphatase activity. Concurrent treatment: cells were exposed to both resveratrol and OIM
throughout the differentiation duration; Pretreatment: cells were cultured in BM/resveratrol conditioned media continuously for certain days prior to
OIM induction; Equal density: Cells were cultured in BM/resveratrol conditioned media continuously for certain days and re-plated at equal density
before OIM induction. Except for the pretreatment groups, all experiments were repeated 3 times independently, with triplicates in each
experimental set. A representative data set is presented for each group and data shown are the relative mean values of triplicates normalized to the
value of the BM control cells in each group. Error bars represent standard deviation. *: p,0.05 vs. BM.
doi:10.1371/journal.pone.0037162.g009
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roles, a dosage intake at the lower scale might be more preferable
until our understanding of the function of resveratrol and its
metabolites is further advanced.
Materials and Methods
Cell culture and differentiation
Human mesenchymal stem cells (hMSCs) were purchased from
Fisher Scientific (SV3010201) and cultured in Hyclone Advance
STEM expansion media (Fisher Scientific, SH30875KT). Passage
4 hMSCs cells were used in all experiments described. For
osteogenic differentiation induction, cells were exposed to an
osteogenic incuding media (OIM) cocktail composed of 0.05 mM
ascorbic acid 2-phosphate (Fisher NC9445523), 10 mM b-
glycophosphate (NC9960188) & 0.2 mM dexamethasone (Fisher
NC9756434) for 14 to 21 days. For adipogenic differentiation
induction, cells were exposed to an adipogenic inducing media
(AIM) cocktail composed of 0.45 mM 3-isobutyl-1-methylxanthine
(Fisher NC9875083), 10 mM insulin (Sigma I9278-5ML), 1 mM
dexamethasone for 18 days.
Resveratrol solution preparation
Resveratrol 100 mM stock solution was prepared fresh every 6
days by dissolving 2.6 mg of resveratrol powder (Sigma R5010-
100 mg) into 100 ml of warm a-MEM (Invitrogen 12571-048) and
filtered. Control solvent is a-MEM (BM). Stored at 4uC.
Resazurin assay
Bioreduction of the dye by viable cells reduces the amount of its
oxidized form (blue) and concomitantly increases the amount of its
fluorescent intermediate (red). Reduction in blue can be measured
spectrophotometrically by monitoring decrease in absorbance at
600 nm (see instructions in Sigma TOX8-1KT). Briefly, 10%
resazurin dye solution (diluted with cell culture media) was added
to cells and incubated for 2 hours in CO2 incubator. Solution was
then transferred to a new empty plate for OD reading at both
600 nm and 690 nm (background).
Cytotoxicity assay
Cytotoxicity assay was carried out by following instructions in
cytotoxicity detection kit (LDH) from Roche (cat # 11644793001).
The assay medium (AM) was composed of DMEM (without
sodium pyruvate) with 1% FBS. Cells were plated at equal density
the day before treatment and LDH enzyme activity was assayed at
24 hours after treatment is initiated. Different treatment groups
were plated in identical matching positions with each other, and
reaction mixture was added in dim light to half wells of each
treatment group sequentially and then to the other half in reversed
order in order to minimize any potential effect of differential
incubation time as a result of the sequence in adding this reagent.
OD reading was derived at 490 nm subtracted by reading at
690 nm using a Biotek ELx800 plate reader and Gen5 ELISA
software.
Apotosis assay
Cell apoptosis assay was carried out by following instructions in
Annexin-V-FLUOS staining kit from Roche (cat # 11 858 777
001). Cells stained positive for Annexin-V alone (green) or both
Annexin-V and PI (red) from each sample well were counted and
imaged using an Olympus IX50 microscope. Cells were then fixed
on the same day and stained with nuclear dye DAPI (Invitrogen
cat # P36931). Total cell numbers in corresponding sample wells
were subsequently counted.
Cell senescence assay
X-gal solution made of 1 mg/ml X-gal (Sigma B9146-100MG,
dissolve in DMSO), 5 mM K3Fe(CN)6 – Potassium ferricyanide
(Sigma 7025870), 5 mM K4Fe(CN)6- potassium hexacyanidofer-
rate(II) (Sigma P9387), 2 mM MgCl2, and 150 mM NaCl in PBS
at pH 6.0 is freshly prepared for each use. Cells were washed 3
times with PBS (pH 7.2) after media removal, fixed with 0.5%
glutaraldehyde (Sigma G7651) for 5 minutes at RT, washed in
PBS (pH 7.2) supplemented with 1 mM MgCl2 (Add 20 ml1M
MgCl2 into 20 ml of PBS) twice and stained in X-gal solution
overnight at 37uC incubator. Stained cells were then rinsed with
PBS once, washed with distilled water twice, at 2 minutes each,
and counter stained with 0.33% neutral red solution (330 mg/
Figure 10. Resveratrol modulates adipogenic differentiation of hMSCs in a dosage dependent manner. A). Oil droplets were stained by
Oil-Red-O solution and subsequently quantified under three different treatment schemes: concurrent treatment, pretreatment and equal density. B).
Images of Oil-Red-O stained cells under different treatment conditions. Concurrent treatment: cells were exposed to both resveratrol and AIM
throughout the differentiation duration; Pretreatment: cells were cultured in BM/resveratrol conditioned media continuously for certain days prior to
AIM induction; Equal density: Cells were cultured in BM/resveratrol conditioned media continuously for certain days and re-plated at equal density
before AIM induction. Except for the pretreatment groups, all experiments were repeated 3 times independently, with triplicates in each
experimental set. A representative data set is presented for each group and data shown are the relative mean values of triplicates normalized to the
mean value of the BM control cells in each group. Error bars represent standard deviation. *: p,0.05 vs. BM. Images were taken at 86except for
bottom row in B) (6.36).
doi:10.1371/journal.pone.0037162.g010
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were taken using an Olympus IX50 microscope.
Cell doubling time assay
Cells were prepared in single cell suspension, diluted to 2-cell/
80 ml media density and plated into 96-well plates with 80 ml/well
cell solution. Wells were examined the next day and 10 wells
containing 1–2 cells were chosen for each treatment condition and
average cell number per well was determined at 0 hour (n) and at
every 12-hour intervals (N). The number of rounds of cell doubling
was determined by LOG(N/n)/LOG(2), which, when divided by
total hours, gave rise to cell doubling time.
Cell cycle assay by DNA content
FACS tubes were pre-coated overnight with 2% Bovine Serum
Albumin (BSA) in PBS. Cells were trypsinized into single cell
suspension, pelleted and washed with ice cold PBS without Ca+2
or Mg+2, collected by centrifugation and re-suspended in cold
PBS (1610
6 cells in 0.5 ml) by vortexing using the lowest speed.
Cell suspension was then slowly added drop wise to an equal
volume of cold absolute ethanol. Cells were then stored at 220uC
for at least 2–24 hours, collected by centrifuge at 1600 rpm for
10 min and washed with 3 ml cold PBS twice. Re-suspended cells
in 500 ml PI/Triton X-100 staining solution prepared fresh (2 mg
DNAse free RNAse A (Sigma R4642) and 0.20 ml of 1 mg/ml PI
(Sigma P4864) were added to 10 ml of 0.1% (v/v) Triton X-100
(Sigma) in PBS), and incubated in 37uC water bath for 15–
30 minutes. Acquired data (Summit v4.3) on flow cytometer
(CyAn ADP-9color, Bechman Coulter) within 48 hours.
Cell proliferation assay
Cell proliferation rate was determined by following the
instructions of the Click-iT EdU Alexa Fluor 488 imaging kit
(Invitrogen C10337). EdU labeling time was 6 hours or 12 hours.
Alkaline phosphatase detection, calcium phosphate
staining and Oil-Red-O staining
Alkaline phosphatase activity was detected by following the
instruction of the Alkaline Phosphatase Staining kit (Sigma,
SD86R). Calcium phosphate was stained by 2% alizarin red
solution PH 4.1–4.3 (Fisher AC40048-0250). Briefly, cells were
fixed in 10% formalin (Fisher SF100-4) for 15 minutes at RT,
rinsed with distilled water 3 times, 5 minutes each, and incubated
in alizarin red solution for at least 20 minutes, followed by rinsing
with water for 4 times, 5 minutes each. Cells were left air dry
before imaging and quantification. Quantification was carried out
Figure 11. Resveratrol regulates the expression of genes implicated in osteogenesis and adipogenesis. A). Representative gel images
of gene expression examined by semi-quantitative RT-PCR on cells subjected to concurrent treatment of BM/resveratrol with OIM for 3 days (OIM 3D-
CT) or 7 days (OIM 7D-CT), or cells pretreated with BM/resveratrol for 12 days followed by 3 days of OIM (12D PT-3D OIM) or 7 days of AIM (12D PT–7D
AIM) exposure. Expression of internal control gene Hsp90 from the same batch of cDNA for each gene is shown in the bottom row. B). Expression of
each gene in resveratrol treated cells was quantified relative to that in BM treated cells and normalized by the expression of housekeeping gene
Hsp90. Data shown are the mean values of three repeats. Error bars represent standard deviation. Concentration unit: mM. *: p,0.05 vs. BM. **:
p=0.055 vs. BM.
doi:10.1371/journal.pone.0037162.g011
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ECM815). Oil droplets inside mature fat cells were stained by Oil-
Red-O solution (Fisher NC9773107). Briefly, cells were fixed in
10% formalin for 20 minutes, rinsed with distilled water 3 times,
washed in 100% isopropylene glycol for 5 minutes, incubated in
Oil-Red-O solution for 30 minutes, washed with 85% isopropy-
lene glycol for 5 minutes and rinsed with distilled water 3 times
before imaging and quantification. For quantification, cells were
air-dried, extracted with pure isopropyl alcohol (Fisher A426P)
and OD was measured at 510 nm.
Gene expression by reverse transcription (RT)-PCR
analysis
Total RNA was isolated from cells with the RNeasy kit
(QIAGEN 74104). SUPERSCRIPT II reverse transcriptase
(Invitrogen 11752050) was used for RT. Primer sequences and
PCR condition for each gene is summarized in table S2.
Statistical analysis
Unpaired student t-test was used to evaluate the statistical
differences between two treatment groups.
Supporting Information
Figure S1 Resveratrol exerts dosage dependent anti- vs.
pro-senescence effect on hMSCs. Percentages of senescent
cells vs. total cells were determined based on images taken on X-
gal stained cells pretreated with resveratrol or BM for 30 days
followed by 5 more days of treatment after equal density plating.
At least 283 total cells from each treatment condition were
counted. Column represents the relative amount of cells
undergoing senescence in each treatment group normalized to
the value of the BM treated cells. Data was obtained from one
experiment.
(TIF)
Figure S2 Resveratrol exerts dosage dependent effect
on osteogenic differentiation of hMSCs derived from
both the adipose tissue (hMSCs-Ad) and bone marrow
(hMSCs-Bm). Cells were exposed to resveratrol/BM and OIM
concurrently for 14 days before calcium phosphate assay. In
hMSCs-Ad, resveratrol reached maximum enhancing effect at
0.1 mM, which gradually decreased as its concentration increased.
Similar effect was also observed in hMSCs-Bm (concentrations at
2 and 3 mM were not examined). Data shown are the mean values
of triplicates. Error bars represent standard deviation. *: p,0.05
vs. BM.
(TIF)
Table S1 Resveratrol induces S-phase arrest in hMSCs
in a dosage dependent manner. Flow cytometry was
performed to analyze cell cycle distributions on cells pre-exposed
to resveratrol or BM for 0 (0D-PT) or 30 (30D-PT) days, followed
by 6 (0D-PT) or 4 (30D-PT) more days of treatment respectively
after equal density plating, and cells cultured in regular hMSCs
media (CM) for 30 days prior to 4 days of resveratrol or BM
treatment following equal density plating (30D-CM). The
percentage of cells in S, G2/M or (S+G2/M) phases in each
treatment group was normalized to the value of the BM treated
cells. Data presented are the mean value from 2 or 3 independent
experiments for each experimental set, except for the 42D-PT set
(cells pretreated with resveratrol or BM for 42 days were plated at
equal density, followed by 4 more days of treatment before
analysis), which was derived from a single experiment. All
duplicate experiments had similar outcomes.
(DOC)
Table S2 Primer sequences and PCR conditions. This
table enlists the primer sequences and PCR conditions used for
gene expression examination by RT-PCR.
(DOCX)
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